Related Experiment Video
Updated: May 3, 2026
07:43
Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
Published on: May 12, 2015
11.7K
Rescuing Neurodevelopmental Deficits in AMPA Receptor Gain-of-Function Mutant
Chih-Ming Chen1, Yu-Min Huang1, Chih-Ching Chung1
1Institute of Cellular and Organismic Biology and Neuroscience Program of Academia Sinica (NPAS), Academia Sinica; Taipei 115, Taiwan.
Biorxiv : the Preprint Server for Biology
|January 9, 2026
Summary
A GRIA1 gene variant linked to autism and intellectual disability causes brain excitotoxicity in mice. An antisense oligonucleotide therapy reversed these effects, showing potential for treating neurodevelopmental disorders.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- AMPA receptors (AMPARs) are crucial for brain function and neuronal development.
- A recurrent variant in the AMPAR GluA1 subunit (GRIA1 p.A636T) is associated with autism spectrum disorder (ASD) and intellectual disability (ID).
Purpose of the Study:
- To investigate the causal role and mechanism of the GRIA1 p.A636T variant in ASD and ID.
- To explore RNA-targeted therapeutic interventions for neurodevelopmental disorders.
Main Methods:
- Generated a GRIA1-A636T knock-in mouse model to study the variant's effects.
- Administered an allele-specific antisense oligonucleotide to silence the mutant GRIA1 transcript in neonatal mice.
Main Results:
- Mutant mice displayed ASD/ID-like behaviors and hippocampal pathology, including dendritic atrophy and neuronal loss.
- AMPARs in mutant mice showed synaptic hyperexcitability and failed to transition to calcium-impermeable forms, leading to excitotoxicity.
- Neonatal antisense oligonucleotide treatment prevented pathology and improved behavioral deficits.
Conclusions:
- The GRIA1 p.A636T variant acts as a gain-of-function mutation, driving developmental excitotoxicity.
- RNA-targeted precision medicine, specifically antisense oligonucleotides, shows promise for treating neurodevelopmental disorders caused by specific genetic variants.
